Gain Therapeutics Inc (GANX) - Total Liabilities
Based on the latest financial reports, Gain Therapeutics Inc (GANX) has total liabilities worth $4.73 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Gain Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Gain Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Gain Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Gain Therapeutics Inc (GANX) total assets.
Gain Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Gain Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Popular Vehicles and Services Limited
NSE:PVSL
|
India | Rs17.55 Billion |
|
Canna Global Acquisition Corp
NYSE:CNGL
|
USA | $11.85 Million |
|
IT City Public Company Limited
BK:IT
|
Thailand | ฿3.40 Billion |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
Turkey | TL402.17 Million |
|
Cps Technologies
NASDAQ:CPSH
|
USA | $4.78 Million |
|
Shotspotter Inc
NASDAQ:SSTI
|
USA | $63.58 Million |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
Turkey | TL3.74 Billion |
|
Renergen Ltd.
JSE:REN
|
South Africa | ZAC1.70 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Gain Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Gain Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gain Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gain Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Gain Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.25 Million | -11.08% |
| 2024-12-31 | $4.78 Million | -20.67% |
| 2023-12-31 | $6.03 Million | +15.54% |
| 2022-12-31 | $5.22 Million | +25.25% |
| 2021-12-31 | $4.17 Million | +22.49% |
| 2020-12-31 | $3.40 Million | +206.48% |
| 2019-12-31 | $1.11 Million | -37.01% |
| 2018-12-31 | $1.76 Million | -- |
About Gain Therapeutics Inc
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and t… Read more